Literature DB >> 31144111

Patients on NOACs in the Emergency Room.

Stefan T Gerner1, Hagen B Huttner2.   

Abstract

PURPOSE OF REVIEW: Despite the increasing use of NOACs, there is still uncertainty on how to treat NOAC patients presenting with neurological emergencies. Initial assessment of coagulation status is challenging but essential in these patients to provide best-possible treatment in case of ischemic or hemorrhagic stroke. Meanwhile, anticoagulation reversal strategies have been suggested; yet, the optimal management is still unestablished. The current review aims to provide up-to-date information on (i) how to identify patients with NOAC intake, (ii) which therapies are feasible in the setting of ischemic and hemorrhagic stroke as well as traumatic intracranial hemorrhage, and (iii) how to proceed with patients requiring emergency lumbar puncture. RECENT
FINDINGS: Despite several expert opinions, there is still an ongoing debate which NOAC patients presenting with ischemic stroke may benefit from recanalizing strategies and whether these treatment approaches can be performed safely. Results from two phase IV trials investigating the efficacy of NOAC-specific reversal agents in case of major bleeding seem promising with regard to hemostatic parameters, but these antidotes have not been verified to clinically benefit patients, and approval by authorities in parts is still pending. Specific reversal agents are on the way and will provide new treatment options in patients with NOAC-related ischemic and hemorrhagic stroke. Up to now, the decision which patients should undergo recanalizing treatment for ischemic stroke, or which specific pharmacological reversal treatment in hemorrhagic stroke should be initiated, has to be made cautiously on an individual basis after assessing hemostatic parameters.

Entities:  

Keywords:  Emergency; Management; NOAC; Oral anticoagulation; Reversal; Stroke

Mesh:

Substances:

Year:  2019        PMID: 31144111     DOI: 10.1007/s11910-019-0954-7

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  104 in total

1.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association.

Authors:  A John Camm; Gregory Y H Lip; Raffaele De Caterina; Irene Savelieva; Dan Atar; Stefan H Hohnloser; Gerhard Hindricks; Paulus Kirchhof
Journal:  Europace       Date:  2012-08-24       Impact factor: 5.214

2.  Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.

Authors:  Trevor Baglin; David Keeling; Steve Kitchen
Journal:  Br J Haematol       Date:  2012-09-13       Impact factor: 6.998

Review 3.  Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

Authors:  Joanne van Ryn; Joachim Stangier; Sebastian Haertter; Karl-Heinz Liesenfeld; Wolfgang Wienen; Martin Feuring; Andreas Clemens
Journal:  Thromb Haemost       Date:  2010-03-29       Impact factor: 5.249

4.  European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.

Authors:  Hein Heidbuchel; Peter Verhamme; Marco Alings; Matthias Antz; Werner Hacke; Jonas Oldgren; Peter Sinnaeve; A John Camm; Paulus Kirchhof
Journal:  Europace       Date:  2013-05       Impact factor: 5.214

5.  Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association.

Authors:  E Sander Connolly; Alejandro A Rabinstein; J Ricardo Carhuapoma; Colin P Derdeyn; Jacques Dion; Randall T Higashida; Brian L Hoh; Catherine J Kirkness; Andrew M Naidech; Christopher S Ogilvy; Aman B Patel; B Gregory Thompson; Paul Vespa
Journal:  Stroke       Date:  2012-05-03       Impact factor: 7.914

6.  Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran.

Authors:  Wei Zhou; Sönke Schwarting; Sergio Illanes; Arthur Liesz; Moritz Middelhoff; Markus Zorn; Martin Bendszus; Sabine Heiland; Joanne van Ryn; Roland Veltkamp
Journal:  Stroke       Date:  2011-10-13       Impact factor: 7.914

7.  Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial.

Authors:  Robert G Hart; Hans-Christoph Diener; Sean Yang; Stuart J Connolly; Lars Wallentin; Paul A Reilly; Michael D Ezekowitz; Salim Yusuf
Journal:  Stroke       Date:  2012-04-05       Impact factor: 7.914

8.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

9.  Lumbar punctures: use and diagnostic efficiency in emergency medical departments.

Authors:  Bilal Majed; Hélène Zephir; Valérie Pichonnier-Cassagne; Yazdan Yazdanpanah; Philippe Lestavel; Pierre Valette; Patrick Vermersch
Journal:  Int J Emerg Med       Date:  2009-11-19

Review 10.  Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.

Authors:  Jonathan Douxfils; François Mullier; Claire Loosen; Christian Chatelain; Bernard Chatelain; Jean-Michel Dogné
Journal:  Thromb Res       Date:  2012-09-21       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.